The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Daratumumab Or Darzalex Market?
The market size for daratumumab or darzalex has experienced swift expansion in recent years. It is anticipated to grow from $5618.3 million in 2025 to $6189.36 million in 2026, achieving a compound annual growth rate (CAGR) of 10.2%. The historical increase in growth can be attributed to its approval for multiple myeloma treatment, strong clinical outcomes targeting CD38, limited alternative options in relapsed disease, widespread adoption by oncology centers, and improved survival rates.
The market size for daratumumab or darzalex is anticipated to experience robust growth over the coming years. It is projected to expand to $9024.5 million by 2030, demonstrating a compound annual growth rate (CAGR) of 9.9%. The projected increase during this period can be attributed to factors such as the broadening of combination regimens, the rising prevalence of multiple myeloma, heightened investment in oncology, the introduction of new indications, and improved patient access programs. Significant trends anticipated during the forecast period include its increasing adoption in multiple myeloma, its use in combination with other oncology drugs, its expansion into earlier treatment lines, the prevalence of hospital-based monoclonal antibody therapy, and its growing application in hematologic malignancies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp
What Influential Factors Are Boosting The Daratumumab Or Darzalex Market Demand?
An increasing occurrence of bone marrow cancer is anticipated to fuel the expansion of the daratumumab or darzalex market in the future. These cancers originate in the bone marrow, encompassing conditions like multiple myeloma and leukemia, leading to abnormal blood cell production that interferes with normal bodily functions. This surge in bone marrow cancer cases stems from an aging global demographic, enhanced diagnostic techniques, and various contributing elements including environmental factors, personal lifestyle choices, and inherited genetic susceptibilities. Daratumumab (Darzalex) aids in managing multiple myeloma, a specific form of bone marrow cancer, by precisely identifying and eliminating aberrant plasma cells within the bone marrow. For example, in January 2025, the American Cancer Society, a non-profit organization based in the US, projected approximately 3,770 new cases of primary bone and joint cancer for 2025 (comprising 2,150 in men and 1,620 in women), alongside an estimated 2,190 fatalities (with 1,240 in men and 950 in women). Consequently, the escalating incidence of bone marrow cancer is a key factor propelling the expansion of the daratumumab or darzalex market.
How Is The Daratumumab Or Darzalex Market Examined Through Segment Analysis?
The daratumumab or darzalex market covered in this report is segmented –
1) By Drug Type: 100Mg Injection, 400Mg Injection
2) By Distribution Channel: Pharmacies, Hospital, Other Distribution Channels
3) By Application: Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma, Other Applications
Which Trends Are Expected To Shape The Daratumumab Or Darzalex Market?
Leading companies in the daratumumab or darzalex market are increasingly directing their efforts towards early intervention oncology treatments, specifically combination therapies, to boost efficacy in managing multiple myeloma and other cancers. These combination therapies represent treatment strategies that utilize two or more therapeutic agents with varied mechanisms of action, frequently working together to enhance effectiveness, minimize drug resistance, and improve patient outcomes, while potentially leading to fewer adverse effects compared to monotherapy. As an illustration, in July 2024, Johnson & Johnson, a US-based pharmaceutical industry company, obtained U.S. FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) used alongside bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in patients with newly diagnosed multiple myeloma (NDMM) suitable for autologous stem cell transplant (ASCT). This latest approval introduces a quadruplet therapy alternative at initial diagnosis, potentially contributing to better patient results.
Who Are The Firms Contributing To The Daratumumab Or Darzalex Market Ecosystem?
Major companies operating in the daratumumab or darzalex market are Genmab A/S, Janssen Biotech Inc.
Access The Complete Daratumumab Or Darzalex Market Report:
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report
Which Region Commands The Largest Share Of The Daratumumab Or Darzalex Market?
North America was the largest region in the daratumumab or darzalex market in 2025. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model